Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Shares Outstanding (Weighted Average) (2016 - 2025)

Sangamo Therapeutics has reported Shares Outstanding (Weighted Average) over the past 16 years, most recently at $280.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 38.92% year-over-year to $280.2 million; the TTM value through Dec 2025 reached $280.2 million, up 38.92%, while the annual FY2025 figure was $280.2 million, 38.92% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $280.2 million at Sangamo Therapeutics, down from $304.3 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $304.3 million in Q3 2025 and troughed at $143.1 million in Q1 2021.
  • A 5-year average of $184.5 million and a median of $172.4 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 2.17% in 2022 and later skyrocketed 46.06% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $144.6 million in 2021, then rose by 6.76% to $154.3 million in 2022, then rose by 13.02% to $174.4 million in 2023, then grew by 15.62% to $201.7 million in 2024, then soared by 38.92% to $280.2 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for SGMO at $280.2 million in Q4 2025, $304.3 million in Q3 2025, and $238.7 million in Q2 2025.